Core Insights - Prelude Therapeutics has demonstrated clinical proof-of-concept for PRT3789, a selective SMARCA2 degrader, showing safety and anti-tumor activity in patients with SMARCA4-deficient cancers [1][2] - The company is advancing its clinical pipeline, with ongoing studies for both PRT3789 and PRT7732, and plans to present additional results in the second half of 2025 [1][2] - Prelude reported a cash position of $133.6 million as of December 31, 2024, which is expected to fund operations into the second quarter of 2026 [1][18] Clinical Development Updates - PRT3789 is in Phase 1 clinical development targeting patients with SMARCA4 mutations, which are associated with poor clinical outcomes [3][4] - The company is nearing completion of monotherapy dose escalation for PRT3789 and is also conducting combination studies with docetaxel [4][9] - A Phase 2 trial evaluating PRT3789 in combination with KEYTRUDA® for SMARCA4-mutated cancers has been initiated [5] Clinical Trial Results - Interim data from the PRT3789 trial indicated that it was generally safe and well-tolerated, with partial responses observed in 5 out of 32 patients with advanced NSCLC or esophageal cancer [7][8] - Among patients treated at doses of 283 mg or higher, 3 out of 13 had confirmed partial responses, and tumor shrinkage was noted in both Class 1 and Class 2 SMARCA4 mutations [8] - The combination of PRT3789 with docetaxel has shown an acceptable safety profile in early cohorts [9] Financial Performance - For the year ended December 31, 2024, Prelude reported a net loss of $127.2 million, or $1.68 per share, compared to a net loss of $121.8 million, or $2.02 per share, in the prior year [21][25] - Research and development expenses increased to $118.0 million from $103.4 million in the previous year, driven by higher patient enrollment in clinical trials [19][25] - General and administrative expenses slightly decreased to $28.7 million from $28.9 million, primarily due to a reduction in stock-based compensation [20][25] Corporate Developments - In February 2025, the company appointed Bryant D. Lim as the permanent Chief Financial Officer [14] - Prelude plans to participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, featuring key executives [15]

Company Participation - Prelude Therapeutics will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025 [1] - The company's executives, including CEO Kris Vaddi, President and CMO Jane Huang, and CFO Bryant Lim, will engage in a fireside chat at 12:30 p.m. ET [2] Company Overview - Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients with high unmet needs [3] - The company's pipeline includes first-in-class SMARCA2 degraders and a potentially best-in-class CDK9 inhibitor, as well as next-generation degrader antibody conjugates [3] - Prelude aims to extend the promise of precision medicine to every cancer patient in need [3]

Core Viewpoint - Prelude Therapeutics Incorporated (PRLD) has experienced significant selling pressure, resulting in a 31.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [1]. Group 1: Stock Performance and Technical Indicators - PRLD's stock is currently in oversold territory, with a Relative Strength Index (RSI) reading of 18.71, suggesting a possible reversal in trend [5]. - The RSI is a momentum oscillator that helps identify oversold conditions when the reading falls below 30, indicating potential entry opportunities for investors [2][3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for PRLD, leading to a 1.6% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6]. - PRLD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Viewpoint - Prelude Therapeutics Incorporated (PRLD) has experienced a significant decline of 39.1% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) for PRLD is currently at 25.3, indicating that the heavy selling pressure may be exhausting, suggesting a possible bounce back towards previous supply and demand equilibrium [3] - Stocks are generally considered oversold when their RSI falls below 30, and the RSI helps identify potential entry points for investors looking to benefit from a rebound [2] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for PRLD will improve, with a 0.5% increase in the consensus EPS estimate over the last 30 days [4] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term, indicating a favorable outlook for PRLD [4] - PRLD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate trends and EPS surprises, further supporting the potential for a turnaround [4]

Financial Performance - The company reported a net loss of $98.4 million for the nine months ended September 30, 2024, compared to a net loss of $88.8 million for the same period in 2023, with an accumulated deficit of $554.8 million as of September 30, 2024[81]. - Net loss for the three months ended September 30, 2024, was $32.3 million, compared to a net loss of $30.6 million in the same period of 2023[93]. - The company used $82.1 million in cash for operating activities during the nine months ended September 30, 2024, reflecting a net loss of $98.4 million[116]. - Cash used in operating activities for the nine months ended September 30, 2023, was $83.5 million, with a net loss of $88.8 million[117]. - The company had a net cash decrease of $14.2 million for the nine months ended September 30, 2024[115]. Revenue Generation - The company has not recognized any revenue from product sales to date and does not expect to generate revenue in the foreseeable future[82]. - Revenue for the three months ended September 30, 2024, was $3.0 million from a license agreement, a recognition of performance obligations related to the exclusive license[94]. - The company recognizes revenue under ASC 606, reflecting the consideration expected to be received for goods or services[120]. Research and Development - PRT3789, a first-in-class SMARCA2 degrader, is currently in Phase 1 clinical development, with initial data showing partial responses in 4 out of 26 evaluable patients with advanced NSCLC or esophageal cancers[78]. - The company initiated a Phase 2 clinical trial for PRT3789 in combination with KEYTRUDA® in patients with SMARCA4-mutated cancers[78]. - PRT2527, a selective CDK9 inhibitor, has shown high levels of target inhibition and a favorable safety profile in a Phase 1 multi-dose escalation study[80]. - The company expects to complete the monotherapy dose escalation for PRT2527 in B-cell malignancies in 2024, with interim data to be presented at the American Society of Hematology Annual Meeting in December 2024[80]. - The company anticipates significant increases in research and development expenses in the coming years as it conducts clinical trials and prepares regulatory filings[88]. - Research and development expenses increased from $26.3 million in Q3 2023 to $29.5 million in Q3 2024, primarily due to increased chemistry, manufacturing, and controls costs[95]. - For the nine months ended September 30, 2024, research and development expenses totaled $86.4 million, up from $73.1 million in the same period of 2023, an increase of $13.3 million[102]. Operating Expenses - Total operating expenses for Q3 2024 were $37.4 million, up from $33.4 million in Q3 2023, reflecting an increase of $3.99 million[93]. - General and administrative expenses rose from $7.1 million in Q3 2023 to $7.9 million in Q3 2024, driven by higher professional fees[97]. - General and administrative expenses for the nine months ended September 30, 2024, were $22.5 million, compared to $21.8 million in the same period of 2023[105]. Cash and Financing - As of September 30, 2024, the company had $153.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026[109]. - The company had $400 million remaining under the 2024 Shelf Registration Statement as of September 30, 2024, which was declared effective on June 10, 2024[112]. - As of September 30, 2024, there was $187 million remaining under the 2021 Shelf Registration Statement, which expires on November 24, 2024[113]. - The company expects to finance operations through equity offerings, debt financings, collaborations, and strategic alliances until substantial product revenue is generated[114]. - Net cash provided by investing activities was $68.1 million for the nine months ended September 30, 2024, primarily from $114.2 million in proceeds from maturities of marketable securities[118]. - Net cash used in financing activities for the nine months ended September 30, 2024, was primarily for principal payments on finance leases and offering costs related to the shelf registration statement[119]. - The company may need to relinquish valuable rights to technologies or future revenue streams if additional funds are raised through collaborations or strategic alliances[114]. Partnerships and Collaborations - A license agreement with Pathos AI, Inc. was established, granting an exclusive license for the PRMT5 inhibitor, PRT811, resulting in a $3.0 million upfront payment and potential milestone payments totaling up to $137 million[83]. - The partnership with AbCellera aims to develop precision antibody drug conjugates, with the first preclinical data demonstrating potent activity in various cancer models[78]. - The company has a diverse pipeline targeting high unmet medical needs, including multiple distinct programs such as kinases and precision antibody drug conjugates[76].

Financial Performance - Prelude Therapeutics reported a net loss of $32.3 million, or $0.43 per share, for Q3 2024, compared to a net loss of $30.6 million, or $0.45 per share, in the same period last year[14]. - General and administrative expenses rose to $7.9 million in Q3 2024 from $7.1 million in Q3 2023, mainly due to increased professional fees[13]. - Accumulated deficit increased from $(456,390,000) to $(554,832,000), indicating a worsening financial position[20]. Research and Development - Research and development expenses increased to $29.5 million in Q3 2024 from $26.3 million in Q3 2023, primarily due to higher chemistry, manufacturing, and controls costs[12]. - PRT3789, a first-in-class intravenous SMARCA2 degrader, is in Phase 1 clinical development, with enrollment on track and monotherapy dose escalation expected to conclude by year-end 2024[4]. - Interim data from the PRT3789 trial showed partial responses in 4 out of 26 evaluable patients with advanced NSCLC or esophageal cancers[4]. - The company initiated a Phase 1 trial for PRT7732, an oral SMARCA2 degrader, with patient enrollment currently ongoing[6]. - Prelude presented preclinical data from its Precision ADC platform, demonstrating potent activity of SMARCA2/4 degrader payloads conjugated to various antibodies[8]. - PRT2527, a CDK9 inhibitor, is advancing in clinical trials, with interim data to be presented at the American Society of Hematology Annual Meeting in December 2024[10]. Financial Position - The company has $153.6 million in cash, cash equivalents, and marketable securities as of September 30, 2024, which is expected to fund operations into 2026[11]. - Total current assets decreased from $235,589,000 on December 31, 2023, to $156,387,000 on September 30, 2024, a decline of approximately 33.5%[19]. - Cash and cash equivalents dropped from $25,291,000 to $11,134,000, representing a decrease of about 56.0%[19]. - Marketable securities decreased from $207,644,000 to $142,492,000, a reduction of approximately 31.4%[19]. - Total stockholders' equity fell from $237,090,000 to $156,431,000, a decline of around 33.9%[20]. - Total liabilities remained relatively stable, increasing slightly from $40,575,000 to $40,789,000[19]. - Accounts payable rose from $4,580,000 to $5,921,000, an increase of approximately 29.3%[19]. - Accrued expenses and other current liabilities decreased from $15,768,000 to $13,579,000, a decline of about 13.9%[19]. - The company reported 42,178,012 shares issued and outstanding as of September 30, 2024, compared to 42,063,995 shares on December 31, 2023[19]. - Additional paid-in capital increased from $693,252,000 to $711,091,000, reflecting a growth of approximately 2.6%[20]. Collaborations - The company has entered into a collaboration agreement with Pfizer Ignite to support its SMARCA2 degrader development programs while retaining full ownership of its programs[7].

Core Insights - Prelude Therapeutics announced the first clinical data for PRT3789, a novel SMARCA2 degrader, targeting patients with advanced solid tumors having a SMARCA4 mutation [1][2] - The company is conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and clinical activity of PRT3789, with enrollment on track and dose escalation expected to conclude by the end of 2024 [1][2] Clinical Trial Details - As of March 7, 2024, 40 patients have been enrolled in the trial, with 55% having loss-of-function mutations [2] - Dose escalation has progressed through 6 levels, ranging from 24 mg to 212 mg, with no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) reported [2] - Common adverse events include nausea (25%), constipation and dyspnea (17.5% each), decreased appetite and fatigue (15% each), and anemia (12.5%) [2] Clinical Activity Observations - Clinical activity noted includes RECIST partial responses, tumor shrinkage, and prolonged stable disease in patients with advanced esophageal cancer and non-small cell lung cancer (NSCLC) [2] - Dose-related increases in area under the curve (AUC) and decreases in SMARCA2 levels were observed, with minimal effects on SMARCA4 levels [2] Upcoming Events - Prelude Therapeutics will host an investor webcast on September 13, 2024, to discuss the findings and provide updates on the clinical trial [1][4] - Updated data will be presented at the European Society of Medical Oncology (ESMO) Congress 2024 [3] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, including first-in-class SMARCA2 degraders and a CDK9 inhibitor [5] - The company aims to address high unmet needs in cancer treatment through targeted protein degradation and next-generation therapies [5]

Financial Performance - The company reported a net loss of $66.2 million for the six months ended June 30, 2024, compared to a net loss of $58.1 million for the same period in 2023, resulting in an accumulated deficit of $522.6 million as of June 30, 2024[70]. - Net loss for the three months ended June 30, 2024 was $34.740 million, compared to a net loss of $30.431 million for the same period in 2023, reflecting a 14.0% increase in losses[79]. - Total operating expenses for the six months ended June 30, 2024 were $71.507 million, up from $61.513 million in the same period of 2023, marking a 16.0% increase[85]. - Research and development expenses increased from $24.966 million in Q2 2023 to $29.509 million in Q2 2024, representing a 18.1% increase[79]. - General and administrative expenses rose from $7.432 million in Q2 2023 to $7.655 million in Q2 2024, a 3.0% increase[79]. - Research and development expenses for the six months ended June 30, 2024 totaled $56.918 million, up from $46.800 million in the same period of 2023, a 21.6% increase[86]. - The company has incurred recurring losses primarily due to research and development activities and negative cash flows from operations[70]. - The company plans to continue incurring significant expenses and operating losses for the foreseeable future as it seeks regulatory approval for its product candidates[70]. Revenue Generation - The company has not recognized any revenue from product sales to date and does not expect to generate revenue in the foreseeable future[71]. - The company has not yet commercialized any product and does not expect to generate revenue from product sales for several years[90]. Research and Development - The company is advancing its first-in-class SMARCA2 degrader, PRT3789, which is currently in Phase 1 clinical development, with expectations to conclude monotherapy dose escalation in 2024[67]. - PRT2527, a selective CDK9 inhibitor, has completed a Phase 1 multi-dose escalation study, showing high levels of target inhibition and a favorable safety profile, with further development planned in hematologic malignancies[68]. - The company expects to present interim Phase 1 data for PRT3789 at the European Society of Medical Oncology (ESMO) Congress 2024 on September 13, 2024[67]. - The company has received IND clearance for its lead oral molecule, PRT7732, which is expected to enter Phase 1 clinical development in the second half of 2024[68]. - The company anticipates significant increases in research and development expenses as it advances its product candidates through clinical trials and prepares for regulatory filings[74]. Cash Flow and Financing - As of June 30, 2024, the company had $179.8 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026[92]. - The company reported a net cash used in operating activities of $54.848 million for the six months ended June 30, 2024, compared to $57.802 million for the same period in 2023[98]. - Cash used in operating activities for the six months ended June 30, 2024, was $54.8 million, compared to $57.8 million for the same period in 2023, reflecting a net loss of $66.2 million in 2024 and $58.1 million in 2023[99]. - Net cash provided by investing activities for the six months ended June 30, 2024, was $57.3 million, primarily from $71.4 million in proceeds from maturities of marketable securities, while net cash used in investing activities in 2023 was $57.4 million[100]. - Net cash provided by financing activities for the six months ended June 30, 2024, was primarily from proceeds received from the issuance of common stock under the employee stock purchase plan, while in 2023 it was $111.1 million from the sale of common stock and pre-funded warrants[101]. - The company plans to raise up to $400 million through a shelf registration statement filed in May 2024 to support ongoing operations and growth strategies[95]. Accounting and Reporting - The company entered into a license agreement with Pathos AI, Inc. in May 2024, granting an exclusive, sublicensable, worldwide license for its PRMT5 inhibitor, PRT811, which will be accounted for under ASC 606[102]. - The company recognizes revenue when the customer obtains control of promised goods or services, reflecting the consideration expected in exchange for those goods or services[102]. - The company has elected to take advantage of exemptions under the JOBS Act, allowing it to delay the adoption of certain accounting standards until they apply to private companies[104]. - The company is classified as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million[106]. - The company may continue to rely on exemptions from certain disclosure requirements as a smaller reporting company, including presenting only the two most recent fiscal years of audited financial statements[106]. - There were no material changes to the company's critical accounting policies and estimates during the three months ended June 30, 2024[103]. - The company is not required to provide quantitative and qualitative disclosures about market risk for the period ending June 30, 2024, as a smaller reporting company[107].

Financial Performance - Prelude Therapeutics reported a net loss of $34.7 million, or $0.46 per share, for Q2 2024, compared to a net loss of $30.4 million, or $0.54 per share, in the same period last year[12]. - Total operating expenses for Q2 2024 were $37.2 million, up from $32.4 million in the prior year period[16]. - Accumulated deficit increased significantly from $456,390,000 to $522,561,000, reflecting a rise of about 14.5%[19]. - Total stockholders' equity decreased from $237,090,000 to $182,276,000, a decline of approximately 23.1%[19]. Research and Development - Research and Development (R&D) expenses increased to $29.5 million in Q2 2024 from $25.0 million in the prior year period, primarily due to increased chemistry, manufacturing, and controls (CMC) expenses[10]. - The interim Phase 1 data for PRT3789, a first-in-class SMARCA2 degrader, is scheduled for oral presentation at the ESMO Congress on September 13, 2024[6]. - Prelude has received IND authorization for PRT7732, its first-in-class oral SMARCA2 degrader, which is expected to enter Phase 1 clinical development in the second half of 2024[8]. - PRT2527, a selective CDK9 inhibitor, is on track to present interim Phase 1 data in Q4 2024, with ongoing dose escalation in both lymphoid and myeloid malignancies[9]. - The company is collaborating with Merck to evaluate PRT3789 in combination with KEYTRUDA® in patients with SMARCA4-mutated cancers, with a Phase 2 trial anticipated to start in Q4 2024[7]. - The company is advancing its clinical programs with a focus on the SMARCA pathway, aiming to address high unmet medical needs in cancer treatment[2]. Cash and Assets - As of June 30, 2024, the company had $179.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2026[10]. - Total current assets decreased from $235,589,000 on December 31, 2023, to $182,714,000 on June 30, 2024, a decline of approximately 22.4%[18]. - Cash and cash equivalents increased from $25,291,000 to $27,828,000, representing an increase of about 10.1%[18]. - Marketable securities decreased from $207,644,000 to $152,016,000, a drop of about 26.8%[18]. Liabilities and Equity - Total liabilities rose from $40,575,000 to $42,015,000, an increase of approximately 3.6%[19]. - Accounts payable increased from $4,580,000 to $6,170,000, an increase of approximately 34.7%[18]. - Accrued expenses and other current liabilities decreased from $15,768,000 to $11,426,000, a decline of about 27.5%[18]. - Additional paid-in capital increased from $693,252,000 to $705,122,000, an increase of approximately 1.3%[19]. - Operating lease right-of-use asset slightly decreased from $30,412,000 to $29,574,000, a reduction of about 2.8%[18]. Educational Initiatives - Prelude has launched an educational video series on SMARCA biology and the development of SMARCA2 degraders, available on its website[5].

Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September Received investigational new drug (IND) authorization for PRT7732, its first-in-class oral SMARCA2 degrader, from the U.S. Food and Drug Administration (FDA) Announced clinical collaboration with Merck to evaluate PRT3789 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients w ...